Abstracts
Appendix to be organized into sections - Dec. 6, 2006
DARPA Restorative Injury Repair:
http://www.darpa.mil/dso/thrusts/bio/restbio_tech/rir/index.htm
Restorative Injury Repair
Program Manager: Dr. Jon Mogford
The vision for the Restorative Injury Repair (RIR) Program is to fully restore the function of complex tissue (muscle, nerves, skin, etc.) after traumatic injury on the battlefield. These injuries include both kinetic (i.e., penetrating wounds) as well as other destructive injuries (chemical and thermal burns, musculoskeletal injuries, blast overpressure, etc.). RIR aims to replace the current concepts of "wound coverage" by fibrosis and scarring with true "wound healing" by regeneration of fully differentiated, functional tissue.
The program will achieve its goals by developing a comprehensive understanding of the wound environment, including cellular elements, matrix, inflammatory mediators, growth factors, nutrients, substrate utilization, biofilms, and ultimately processes of morphogenesis leading to anatomic and functional restoration. This is an extremely aggressive, milestone-driven program, with a Phase 1 effort focused on defining the wound environment and generating a blastema in an otherwise non-regenerating animal. This will be followed by a Phase 2 effort, which will culminate in the restoration of a functional multi-tissue structure in a mammal.
National Center for Rehabilitative Auditory
Research (NCRAR)
Director's Meeting for VA Centers of Excellence
in Rehabilitiaton Research and Development, which Portland
- talk on blast trauma by Dr. Lew
of the Palo Alto VA Polytrauma Center. A short article by Dr. Lew is a useful
summary of some of the research issues associated with blast trauma:
http://www.vard.org/jour/05/42/4/pdf/lew.pdf (password
protected site)
Eric E. Sabelman, PhD recommends a very thorough & up-to-date review of new SCI approaches (cell implants, tissue engineering, etc):
Therapeutic interventions after spinal cord injury: Nature Reviews ...,
Thuret, Moon & Gage, authors, Aug, 2006
http://www.nature.com/
Bleeding in Massive Trauma - Information Packet
Leo R. Zacharski
A packet of information illustrating the range of therapies available for such "prohemostatic" therapy. Aprotinin is of special interest because it is non-toxic, and both prohemostatic and antithrombotic. It is FDA approved for blood sparing in CABG surgery.
Lisa Vande Vusse, Medical House Staff, is working with us on a report of about a half dozen cases having difficult bleeding problem that we treated successfully with aprotinin here at DHMC. There are, therefore, several options to consider that should be much less expensive and less toxic than recombinant facto VIIa.
Address comments or questions to Lisa.K.Vande.Vusse@Hitchcock.ORG or Leo.R.Zacharski@Dartmouth.edu.
Burn Unit -Brigham and Women's Hospital
http://www.brighamandwomens.org/research/research.aspx
http://www.brighamandwomens.org/BurnTrauma/BurnCenter/BurnCenterMain.aspx
Dennis P. Orgill, M.D., Ph.D.
Associate Chief of Plastic Surgery
Director, Burn Unit
Brigham and Women's Hospital
Assistant Program Director
Combined Harvard Plastic Surgery Residency
Boston dorgill@partners.org